Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Hamburg - Delayed Quote EUR

GSK PLC (GS70.HM)

Compare

36.00

+0.20

+(0.56%)

At close: February 28 at 5:25:15 PM GMT+1

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

PHILADELPHIA, February 17, 2025--PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY

Business Wire 12 days ago

GLAXF

GSK
Trending tickers: TSMC, Tencent, Alibaba, GSK and BAE Systems

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 12 days ago

AVGO

BHP

BHPLF
GSK shares shorted by leading U.S. hedge fund, The Times reports

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s stock for more than a decade, The Times’ Ben Martin reports. Citadel, the $65B American investment firm, has built a net short position equating to 0.51 percent of GSK’s issued share capital, according to filings with the Financial Conduct Authority, the City regulator. It is the first time since late 2013 that an investor has amassed a short in GSK that

TipRanks 13 days ago

GLAXF

GSK
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Simply Wall St. 14 days ago

GLAXF

GSK
Hedge fund Citadel takes short position in GSK, FT reports

Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, according to data from the Financial Conduct Authority, the FT report said. Citadel did not immediately respond to a Reuters request for comment. A short position represents a bet that a company's stock will fall in value.

Reuters 14 days ago

GLAXF
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1

CNW Group 15 days ago

GLAXF

GSK

PFE
Some May Be Optimistic About GSK's (LON:GSK) Earnings

GSK plc's ( LON:GSK ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed...

Simply Wall St. 17 days ago

GLAXF

GSK
Recent uptick might appease GSK plc (LON:GSK) institutional owners after losing 7.8% over the past year

Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...

Simply Wall St. 19 days ago

GLAXF

GSK
The most popular stocks and funds for investors in January

The first month of 2025 was a busy one for markets, and platforms have revealed which were the most popular stocks and funds with investors in January.

Yahoo Finance UK 23 days ago

BTC-USD

TWODF

TWODY
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales.

Investor's Business Daily 23 days ago

GLAXF

GSK
Trending tickers: Alphabet, Advanced Micro Devices, PayPal, Novo Nordisk and GSK

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 24 days ago

UBER

^FTSE

^DJI
FTSE 100 Live 05 February: GSK shares surge on new guidance, gold at record price

An improved long-term sales target today revitalised GSK shares after their dismal 2024. Mining stocks also rallied today after the price of gold set another record high. GSK dominated a steady FTSE 100 index today after the drugs giant’s long-term guidance helped to revitalise shares following their dismal showing in 2024.

Evening Standard 24 days ago

GLAXF
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

Investor's Business Daily 24 days ago

BNTX

PFE

GLAXF
GSK announces EMA accepted for review the MAA for depemokimab

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium to high dose corticosteroids plus another asthma controller and also as an add-on

TipRanks 30 days ago

GLAXF

GSK
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings

Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS.

Investor's Business Daily 30 days ago

PFE

GLAXF

GSK
GSK and Oxford researchers to create cancer vaccine to stop disease developing

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

PA Media: Money last month

GLAXF
Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

The latest investor updates on stocks that are trending on Monday

Yahoo Finance UK last month

^FTSE

BABA

BABAF
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordi

TipRanks last month

NONOF

NVO

BMY
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Yahoo Finance last month

AZN

AZNCF

TEVA
Healthcare M&A poised for a rebound in 2025

The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK). Maurits Pot, CEO of Tema ETFs, joins Market Domination to give his predictions for continued M&A growth, specifically within the oncology, neuroscience, and metabolic sectors. Pot reflects on the challenges faced by the healthcare sector in 2024 and the outlook for the coming year. "2024 was, again, a pretty muted year for healthcare M&A, overall, a muted year for the healthcare sector and a number of big companies did not do many big acquisitions," Pot's says. "We think there will be a material pick up this year." Pot also discusses challenges in the GLP-1 market but cites innovation in drug delivery. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Josh Lynch

Yahoo Finance Video last month

JNJ

GLAXF

GSK

Performance Overview

Return	GS70.HM	FTSE 100
YTD	+11.69%	+7.79%
1-Year	-2.16%	+15.54%
3-Year	+7.17%	+18.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GSK PLC (GS70.HM)

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

Trending tickers: TSMC, Tencent, Alibaba, GSK and BAE Systems

GSK shares shorted by leading U.S. hedge fund, The Times reports

Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend

Hedge fund Citadel takes short position in GSK, FT reports

ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis

Some May Be Optimistic About GSK's (LON:GSK) Earnings

Recent uptick might appease GSK plc (LON:GSK) institutional owners after losing 7.8% over the past year

The most popular stocks and funds for investors in January

GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion

Trending tickers: Alphabet, Advanced Micro Devices, PayPal, Novo Nordisk and GSK

FTSE 100 Live 05 February: GSK shares surge on new guidance, gold at record price

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

GSK announces EMA accepted for review the MAA for depemokimab

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings

GSK and Oxford researchers to create cancer vaccine to stop disease developing

Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Healthcare M&A poised for a rebound in 2025

Performance Overview